Organization · Venture Capital
Alix Ventures
Alix Ventures is a seed-stage venture capital fund based in San Francisco, focusing on early-stage life sciences startups, particularly in the TechBio sector. The firm supports companies that integrate technology and biology to innovate in human health.
Overview
What Alix Ventures does
What Alix Ventures is
Alix Ventures is a seed-stage venture capital fund based in San Francisco, focusing on early-stage life sciences startups, particularly in the TechBio sector. The firm supports companies that integrate technology and biology to innovate in human health.
How it participates in the startup ecosystem
The current public profile supports funder capabilities. Each capability below is shown separately so organization identity and role-specific information do not get conflated.
Operational profile
Organization status and context
Organization status describes the entity itself. Funding and program availability appear within the relevant capability profile.
- Operational status
- Active
- Organization type
- Venture Capital
- Founded
- Founded in 2019
- Approximate age
- About 7 years
- Structured capabilities
- Funder
- Last reviewed
- April 29, 2026
Official channels
Find Alix Ventures elsewhere
Open the official website or a supported primary organization account.
Capability profile
Alix Ventures as a funder
Investment thesis
Alix Ventures backs early life-science platform companies that combine technology and biology to improve patient outcomes.
Focus narrative
Alix Ventures invests in the life sciences sector, particularly in companies that are part of the emerging 'TechBio' landscape. The organization supports startups developing solutions in drug development, tech-enabled diagnostics, genomic data platforms, and clinical trial platforms, with a primary focus on companies that drive patient impact.
Value beyond capital
Alix Ventures provides extensive support to its portfolio companies, including fundraising assistance, customer introductions, hiring help, KPI guidance, and access to a network spanning pharma, health systems, and payors.
Terms and economics
- Typical check
- $100,000–$500,000
Focus and fit
- Stages
- Pre-seed · Seed · Series A
- Sectors
- Biotech · Healthcare · Diagnostics · Synthetic Biology · Precision Medicine
- Regions
- United States
Availability
- Currently deploying
- Yes
Portfolio and track record
- Recorded portfolio count
- 14
- Recorded notable exits
- Circularis
Portfolio context
Xilis: Enabling precision medicine through patient-derived micro-organoids. Elegen: Enabling full-stack DNA writing. 64x: Enabling viral vector manufacturing. Mythic: Enhancing therapeutic potency to optimize treatments. Endpoint: Enabling precision immunology. Zafrens: Enabling high-throughput single-cell screening. Teiko: Enabling next-generation immune system profiling. Circularis: Acquired by Ginkgo Bioworks, empowering gene therapy optimization. Galatea: Enabling genomic insights for underrepresented populations. Basil Systems: Enabling actionable life science business intelligence. Clora: Empowering premier life science talent placement. Pair Team: Enabling care coordination as a service. STRM: Enabling non-viral gene delivery. Exthymic: Enabling next-generation cell therapy manufacturing.
Common questions
What to know about Alix Ventures
Upseed classifies Alix Ventures under the Venture Capital organization type. Its current public profile includes funder capabilities.
Source and update disclosure
Know what this page is based on
Source basis
Public organization and program material, official websites, and structured Upseed records.
Last reviewed
April 29, 2026
Known limits
Capability profiles appear only when a structured public profile also contains decision-useful role evidence. Terms and availability can change.
Upseed is an independent guide. It is not affiliated with or endorsed by the organization described on this page.